NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares [Yahoo! Finance]
Neuropace, Inc. (NPCE)
Company Research
Source: Yahoo! Finance
disorders through responsive neurostimulation, has reported an insider sell transaction. According to a recent SEC filing , the insider, Chief Medical Officer Martha Morrell , sold 13,848 shares of the company on February 1, 2024. Warning! GuruFocus has detected 10 Warning Signs with NPCE. Over the past year, the insider has sold a total of 41,813 shares and has not made any purchases of the stock. The recent transaction is part of a trend observed over the past year, where there have been no insider buys and eight insider sells for NeuroPace Inc. On the date of the sale, shares of NeuroPace Inc were trading at $15.09, valuing the company at a market cap of approximately $393.992 million. The stock's valuation, when compared to the GuruFocus Value (GF Value) of $6.52, indicates a price-to-GF-Value ratio of 2.31. This suggests that NeuroPace Inc is significantly overvalued according to the GF Value metric. The GF Value is determined by considering historical trading multiples
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024GlobeNewswire
- NeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceGlobeNewswire
- Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]Yahoo! Finance
- NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.MarketBeat
NPCE
Earnings
- 3/5/24 - Beat
NPCE
Sec Filings
- 5/3/24 - Form 4
- 4/26/24 - Form 4
- 4/23/24 - Form 4
- NPCE's page on the SEC website